National Comprehensive Cancer Network

About NCCN

UPDATES: NCCN Guidelines® and NCCN Compendium®

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Acute Lymphoblastic Leukemia (ALL). These NCCN Guidelines® are currently available as Version 3.2013.

 

  • Relapsed/Refractory Ph-positive ALL (ALL-D 3 of 4)
    • Bosutinib added as a treatment optio  for patients with mutations E255K/V, F317L/V/I/C, F359V/C/I, T315A or Y253H.
    • Based on the revised FDA labeling, ponatinib added as a treatment option with the following footnote: “Ponatinib has activity against T315I mutations and is effective in treating patients who have failed multiple TKIs. However, it is associated with a high frequency of serious vascular events (e.g. strokes, heart attacks, tissue ischemia). The FDA indications are for the treatment of adult patients with T315I positive Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) and for the treatment of adult patients with Ph+ ALL for whom no other TKI therapy is indicated. For details, see http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203469s007s008lbl.pdf. “
    • Dasatinib clarified with the following footnote: “For patients with mutations Y253H, E255K/V or F359V/C/I.”
    • Nilotinib clarified with the following footnote: “For patients with mutations F317L/V/I/C, T315A or V299L.”

*For your reference, the announcement of the previous update (Version 2.2013) to the NCCN Guidelines for ALL,distributed on November 4, 2013, is included below:

NCCN has published updates to the NCCN Guidelines and the NCCN Compendium® for Acute Lymphoblastic Leukemia (ALL). These NCCN Guidelines are currently available as Version 2.2013.

Following the Drug Safety Communication issued October 31, 2013 by the FDA regarding the safety issues with ponatinib (increased frequency of blood clots and narrowing of blood vessels), the agent has been removed as a treatment option for patients with ALL until further discussion by the NCCN ALL Guidelines Panel. 

For the complete updated versions of the NCCN Guidelines, NCCN Compendium®, and the NCCN Chemotherapy Order Templates (NCCN Templates®), please visit NCCN.org.

To access the NCCN Biomarkers Compendium™, please visit NCCN.org/biomarkers.

To view the NCCN Guidelines for Patients®, please visit NCCN.com.

Free NCCN Guidelines apps iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.

About NCCN Flash Updates™ 

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium, and other NCCN Content. 

Subscribe to NCCN Flash Updates™ 

National Comprehensive Cancer Network® (NCCN®)

275 Commerce Drive, Suite 300

Fort Washington, PA 19034

Telephone: +1 215.690.0300 Fax: +1 215.690.0280 

Access information on permissions and licensing of NCCN Content  

© 2014 National Comprehensive Cancer Network. All Rights Reserved.